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complicated by numerous drug, diet, and metabolic 
interactions.[2]
In patients with unprovoked VTE, long-term 
anticoagulant treatment is highly eﬀ ective in preventing 
recurrent VTE, the risk of a recurrent event in the 1st 
year following discontinuation of anticoagulation 
varies from 5% to 15%, and such duration of therapy is 
controversial, but the optimal duration of this therapy 
remains uncertain. After oral anticoagulant therapy 
(OAT) withdrawal, the recurrence of risk is greatest in 
the 1st year and gradually diminishes while the increased 
bleeding risk may offset the benefits of prolonged 
OAT.[3,4] After the fi rst 3 months, the American College of 
Chest Physicians recommends an individual evaluation 
INTRODUCTION
Approximately, 900,000 people are diagnosed with 
venous thromboembolism (VTE) annually with 5% 
Americans experiencing a deep vein thrombosis (DVT) 
during their lifetime.[1] Immediate mortality associated 
with DVT has been estimated at 5%, but cumulative 
mortality in the fi rst 6 months after a thromboembolic 
event is 5-10% increasing to 20% by 2 years, mainly 
because of malignancy.[2]
Under-anticoagulation with a Vitamin K antagonist 
(VKA), increases the risk of thrombotic events, and over-
anticoagulation increases the risk of serious bleeding. 
The narrow therapeutic range of VKAs is further 
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for the risk-benefi t ratio of long-term therapy in patients 
with unprovoked VTE for their relevant risk of recurrence.[5] 
Hence, the benefi ts of extending anticoagulation should be 
balanced against the risk of bleeding.[6]
New parameters have, however, been proposed to 
optimize OAT duration; among them, D-dimer assay and 
measurement of residual thrombosis on ultrasonography, 
so-called residual vein obstruction (RVO) were proposed to 
be eﬀ ective in selecting patients with idiopathic DVT who 
may benefi t from a prolonged anticoagulation.[3,4]
D-dimer levels were shown to have a high negative 
predictive value (NPV) for recurrent VTE. So far only one 
randomized trial, the prolong study, has been performed 
to establish the role of D-dimer for assessing the risk of 
recurrence after a fi rst episode of VTE.[6] On the other 
hand, RVO might impair venous fl ow, leading to stasis 
and activation of the coagulation cascade, or be a surrogate 
marker for a hypercoagulable state. Whereas some 
previously published studies have shown an association 
between RVO and recurrent VTE, others have not. It is 
unknown D-dimer could be a predictor of cardiovascular 
events and occult cancer in subjects with a fi rst episode of 
idiopathic proximal deep vein thrombosis (DVT).[3,6-8]
The purpose of the current study was to determine the rate 
of VTE recurrence and predictive values of D-dimer test 
after OAT withdrawal according to the results of D-dimer 
in patients with idiopathic DVT.
MATERIALS AND METHODS
Study design
This single center prospective study was conducted in 
patients with a fi rst episode of symptomatic proximal DVT, 
detected by compression ultrasonography (CUS), and who 
received OAT for at least 3 months.
Those who agreed to participate in the study underwent 
an examination to assess baseline clinical conditions and 
to exclude contraindications. Study enrolment started on 
September 2011 and ended on June 30, 2012 at Alzahra 
Hospital in Isfahan. Follow-up was extended from October 
30, 2011, to August 21, 2013. After enrolment, patients were 
re-evaluated at 1st, 6th and 12th months of their follow-up 
[Figure 1].
Study patients
Patients with a fi rst episode of documented idiopathic 
proximal DVT were eligible for the study if they had 
completed at least 3 months of OAT with reaching target 
international normalized ratio between 2.0 and 3.0.
Idiopathic DVT[6] was defi ned as a thrombosis episode 
in apparently healthy individuals with the absence of 
pregnancy or puerperium, recent fracture or plaster casting 
of a leg, immobilization with confi nement to bed for 3 
consecutive days, active malignancy, known thrombophilic 
states, using precipitating drugs and surgery with general 
anesthesia lasting >30 min during the last 3 months.
Patients with secondarily DVT such as severe liver 
or renal insufficiency (glomerular filtration rate <30), 
antiphospholipid antibody syndrome, other known 
thrombophilic states (such as defi ciencies of antithrombin 
and protein C and S, homozygous for FV Leidenm or 
prothrombin gene (20210G_A) mutations, coexistence 
definite indications for cardiac or cerebral for using 
anticoagulation, limited life expectancy, or those who lived 
too far from the research center did not include.
The duration of anticoagulation based on CUS and D-dimer 
study was approved by our university research commiĴ ee 
(University Research Project Number 391015). All enrolled 
patients provided wriĴ en informed consent.
On the day of VKA discontinuation, CUS of the lower limbs 
was performed by investigators unaware of the laboratory 
fi ndings of D-dimer. Hence, lumen compressibility was 
assessed by pressure of the probe; RVT diameter was 
taken by measuring the distance between the anterior 
and posterior walls of the vein, on freeze frame of B-mode 
images, during compression with the ultrasound probe. 
RVT was arbitrarily scored as “absent” when the fi gure was 
40% or less of the vein diameter.
All patients with present RVT at the beginning of this study 
were excluded D-dimer was assessed using the VIDAS® 
D_Dimer exclusion II™ (DEX2) qualitative, whole blood 
method assay (BIOMÉRIEX, Marcy, France; cut-oﬀ : 500 ng/
ml) by technicians unaware of the clinical characteristics 
of the patients. Anticoagulation was stopped on the same 
day, and the next visit was scheduled after 30-day. Patients 
with recurrent events before the 30-day visit were excluded 
from further analysis.
Figure 1: Schematic diagram of patients selection and follow-ups in this study 
hazard ratio for D-dimer at T0 hazard ratio for D-dimer at T1
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At the 30-day visit, venous blood samples were taken for 
D-dimer repeated test. All enrolled patients (with and 
without RVT) were stopped OAT.
Study outcomes and follow-up
Patients were followed for about 12 months after OAT 
discontinuation. Study outcomes were recurrent VTE. 
Patients were trained to contact the clinical center if 
symptoms developed suggestive of VTE or bleeding. In 
cases of recurrence, results of CUS were compared with 
those of the previous examination. Diagnosis of recurrent 
DVT was made if a previously fully compressible segment 
(contralateral or ipsilateral) became no longer compressible 
or if an increase of 40% or more in the diameter of the 
residual thrombus during compression was detected. In 
patients with suspected pulmonary embolism, diagnosis 
of VTE recurrence was based on results of D-dimer 
assay, pulmonary computed tomography angiography or 
pulmonary ventilation/perfusion scanning. Although in 
the case of low clinical pretest probability, D-dimer was 
measured and if normal, patients were not investigated 
further. In case of suspected recurrence in the contralateral 
leg of the index event, patients with negative CUS and 
normal D-dimer (cut-oﬀ : 500 ng/ml) were not investigated 
further. In the case of negative CUS and abnormal D-dimer, 
a repeated CUS was scheduled after 5-7 days. If the repeated 
CUS was negative, patients were not investigated further. 
In the case of a suspected DVT recurrence in the same leg 
of the index event, CUS results were compared with the 
results of the last available previous CUS. If the CUS was 
nondiagnostic and D-dimer normal, a repeated CUS was 
scheduled after 5-7 days.
We scheduled a follow-up visit at 1, 6 and 12 months after 
stopping of VKA for all patients. At each follow-up visit, 
we examined patients and inquired about health status, 
clinical symptoms or signs of recurrent VTE, bleeding, 
posĴ hrombotic manifestations, adherence to treatment, 
and concomitant analgesic or antiinflammatory therapy. 
D-dimer was assessed only at the fi rst and the end of 
1st month of patients follow-up.
Patients received a card with the telephone numbers of 
the thrombosis centers and were instructed to return 
to the study center if clinical manifestations suggestive 
of recurrent venous thrombosis in either leg (edema, 
redness, tenderness, pain, or swelling), or pulmonary 
embolism (dyspnea, chest pain, or tachycardia) occurred. 
If this was the case, we invited patients to the Alzahra 
Hospital (research center ) for further diagnostic 
procedures. At fi rst, all patients were requested to wear 
40 mmHg elastic stockings for >2 years. In the case of 
suspected recurrent event, D-dimer was sampled only 
for diagnostic purposes.
Statistical analysis
We used the Chi-square test to compare the rate of persistent 
residual venous thrombosis at the last ultrasonography 
assessment and also abnormal D-dimer at 0, 1 month 
between the two groups. Diﬀ erences between groups were 
assessed by the Fisher’s exact test, Chi-square test (Yates’ 
correction) or t-test when appropriate. Approximately, 95% 
confi dence intervals (95% CI) were calculated based on 
the binomial distribution. Hazard ratio was calculated to 
assess the risk for recurrent VTE for patients with abnormal 
D-dimer versus those with normal D-dimer at both T0 and 
T1 versus those without. Kaplan — Meier estimates and 95% 
CI were calculated to assess the risk for recurrent VTE for 
patients with abnormal D-dimer versus those with normal 
D-dimer at both T0 and T1.
A two-sided P ≤ 0.05 was considered as statistically 
significant. The SPSS software package (13.0 release, 
Chicago, IL, USA) was used for data processing.
RESULTS
Patients
A total of 68 eligible patients were enrolled since March 2011 
at medical clinics of Alzahra Hospital. Figure 1 shows the 
study fl ow chart of the 68 patients included in the study. 
After excluding four patients (two patients need to use 
long-term oral anticoagulation, and another two patients 
were excluded for lost to their fi rst follow-up). Therefore, 
64 patients were enrolled at the end of 1st month. D-dimer 
and CUS at fi rst was normal in 28 patients (44%) while the 
remaining 36 patients had abnormal D-dimer but normal 
CUS (both groups did not consuming their anticoagulant). 
The baseline characteristics of the two groups of patients 
are reported in Table1. Patients with normal D-dimer results 
were more likely to be younger (P < 0.03) [Table 1].
Follow-up
A follow-up of 12 months was available in 44 patients 
(68%). We have no reports of D-dimer at T1 in two patients 
but these patients were returned to our study in the next 
follow-up. In the extended follow-up, no patients were lost.
Outcomes
Recurrent venous thromboembolism
During follow-up, three recurrent events were recorded 
(4.6% of patients - 95% CI: 3-7%) [Table 2]. Recurrent 
events were ipsilateral in all cases. Among these patients, 
all had an abnormal D-dimer at either T0 and/or T1. The 
recurrence rate was higher in males than in females (8.6% 
vs. 2.2%) with an abnormal D-dimer at T0 and/or T1 with 
a multivariate hazard ratio of 2.1 (95% 1.2-7; P = 0.04). 
However, the rate of recurrence did not diﬀ er in relation 
to VKA duration among the patients who had been treated 
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for ≤5 or >5 months, respectively (hazard ratio 1.4: 95% CI: 
0.8-4.8; P = 0.06). Patients older than 65 years had a higher 
rate of events than younger patients (2/12: 16%; 95% CI: 
4-24% vs. 1/52: 2%; 95% CI: 0.05-3%) and hazard ratio was 
about 3.8; (95% CI: 1.95-8.4 P = 0.04).
Table 2 shows the rate of primary outcomes by treatment 
assignment. Event rates were significantly higher in patients 
with an abnormal D-dimer did not resume anticoagulation 
drugs than those with a normal D-dimer.
D-dimer at T0 and T1
Patients with recurrences had higher mean D-dimer at 
both T0 and T1 time when compared with those without 
recurrences, but the diﬀ erence was signifi cant only for 
D-dimer at T1 (mean ± standard error; 593 ± 81 vs. 343 ± 
35 ng/ml at T0, P = 0.04; 638 ± 57 ng/ml vs. 435 ± 35 ng/ml 
at T1, P < 0.01).
The characteristics of patients according to D-dimer at T0 
and T1 time, classifi ed as normal or abnormal (cut-oﬀ  500 ng/
ml) are shown in Table 1. All patients who had an abnormal 
D-dimer at T0 had also an abnormal D-dimer at T1. The rate 
of abnormal D-dimer increased signifi cantly at T1 when 
compared to T0 (P < 0.01). The characteristics of subjects 
with an abnormal or normal D-dimer either at T0 or T1 were 
similar except for a signifi cant older age among subjects with 
abnormal D-dimer at both time points and a higher rate of 
males with a normal than with an abnormal D-dimer at T1.
The cumulative incidence of recurrence for D-dimer both 
at T0 and T1 are shown in Figure 2.
Deaths
During follow-up, two patients died (3%). The cause of 
death was aĴ ributed to VTE in only one subject and to 
ischemic heart disease in another. All these patients had 
abnormal D-dimer at zero time [Table 2].
When death or VTE was used as the end point of study, 
sensitivity of D-dimer was maintained at 100%. The VIDAS 
test at time of drug withdrawal had a Specifi city of 67%, 
giving a negative likelihood ratio of 1.41. Table 3 shows 
the D-dimer test characteristics at two diﬀ erent times in 
this study.
The sensitivity and NPV of D-dimer at T0 and T1 was 
similar. Specifi city was 67.3% at T0 and 79% at T1. PPV of 
the test was 14.3% at T0 and 23% at T1.
DISCUSSION
In this single center study, we have evaluated a population 
of patients with idiopathic DVT presenting to a general 
hospital thrombosis center.
In our cohort of DVT patients, the annual risk of recurrence 
with an abnormal D-dimer, either during or at 1-month 
after VKA withdrawal, was 4.6% which is much lower 
to the annual risk of recurrence in most studies with 
idiopathic and provoked VTE.[5] Prandoni[7] reported that 
the cumulative incidence of recurrent VTE was 11% and 
Young et al.[2] in 2006 showed that recurrence rate was 
only 4%.[2-7] According to patient selection, our results 
were contributed to idiopathic DVT results as shown in 
Young study.
Our results also demonstrated that in subjects with 
idiopathic DVT, an abnormal D-dimer, either at the end of 
treatment or at 1-month after VKA withdrawal, is associated 
with a higher risk of recurrence than a normal D-dimer.
In 2010, PROLOG study, confirmed that an abnormal 
D-dimer measured 1-month after VKA withdrawal is 
associated with a significantly higher risk of recurrence 
than normal D-diner in patients with proximal DVT of 
Table 2: rate of primary outcomes by treatment 






Death/total (%) 0/28 (0) 2/36 (5.5) 2/64 (3.1) 0.03




Recurrence 0/28 3/36) 8.3) 3/64 (4.6) 0.02
VTE = Venous thromboembolism
Table 1: The baseline characteristics of the two groups of patient
Variables D-dimer at T0 (fi rst) D-dimer at T1 (after 1-month)
Normal Abnormal Total P value Normal Abnormal Total P value
Number 28 36 64 26 36 62a
Male 12 (54) 20 (55) 32 (50) 0.5 14 (53) 18 (50) 28 (51) 0.4
Age, median (year) 42 57 50 0.03 44 55 50 0.2
Age over 65 years (%) 5 (18) 10 (30) 15 (22) 0.03 8 (30) 14 (39) 22 (35) 0.2
VKA duration (month) 8.3±0.6 7.7±0.4 8.1±0.3 0.2 8.7 8.4 8.5 0.3
Recurrence rate 0 (0) 3 (8.3) 3 (5.5) 0.04 0 (0) 3 (8.8) 3 (5.8) 0.2
Follow-up (months) 10.8±0.7 9.9±0.5 10.2±0.4 0.3 10.8±0.8 9.8±0.5 10.2±0.4 0.4
aIn 2 subjects results for D-dimer at T1 was not available; VKA = Vitamin K antagonist; SD = Standard deviation; The results are presented as number (%) or mean ± SD where appropriate
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the lower limbs.[9] Besides, Bruinstroop et al., in 2009, 
showed that elevated D-dimer level measured 1-month 
after discontinuation of OAT identify patients with 
idiopathic VTE at a significantly higher risk of recurrent 
VTE.[10]
Results of the extended follow-up of the PROLNG 
study confirmed the benefit of prolonging VKAS in 
patients with an abnormal D-dimmer at 1-month after 
anticoagulation withdrawal. These results strengthen the 
fi nding that D-dimmer is associated with the individual 
risk of recurrence after a fi rst episode of unprovoked 
VTE. The optimal course of therapy in patients with 
normal D-dimmer remains unclear also with the extended 
follow-up.
Contrary, Baglin et al., evaluated patients with nonsurgical 
provoked VTE over a median follow-up of 36 months. 
Results showed that post anticoagulation D-dimmer was 
not predictive of recurrent evens over the follow-up.[11]
The NPV of D-dimmer in our study was 100% which was 
near to results of verhovesk at all, (NPV of D-dimmer was 
92%) and in the study by Bruinstroop et al. and Palareti 
et al. were 93%.[10,12,13]
The AESPUS and DACUS studies was conducted in patients 
with both provoked and unprovoked DVT, but only patients 
with unprovoked DVT were enrolled in our study.[3,14] 
Neither the AESPUS nor the DACUS studies evaluated RVO 
in combination with D dimmer, but PROLONG study do it. 
PROLONG study is the only randomized study evaluating 
both parameters.[9,15]
In our study, no eﬀ ect of the presence of RVO was observed 
possibly due to the small number of events and the small 
sample size.
The study also demonstrates that patients with a confi rmed 
diagnosis of DVT have signifi cant cumulative mortality 
with rates of 3% at the end of 1st year, which was similar to 
Young results, with 4%, 12% and 27% at 1, 2, and 5 years, 
respectively.[2]
CONCLUSION
This study confirms that D-dimmer at the time of 
withdrawal and 1-month after VKA discontinuation is an 
independent risk factor for recurrent VTE after a single 
episode of idiopathic proximal DVT of the lower limbs and 
very useful for the clinicians in selecting patients at high 
risk of recurrent VTE.
Study limitations
This study has some limitations. The sample size was 
not calculated to assess the relative risk of cardiovascular 
events, death and cancer. Future studies should focus on 
determining optimal D-dimer cut-oﬀ  level and optimize 
multi risk factor model and duration of extended therapy 
in patients with elevated D-dimmer levels.
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